What Zynerba’s Flop Means For CBD Therapies And GW Pharmaceuticals

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) lost more than 58 percent of their value Monday morning after the company reported disappointing results from its phase 2 STAR 1 clinical trial Continue reading “What Zynerba’s Flop Means For CBD Therapies And GW Pharmaceuticals”

GW Pharma Takes A Step Toward Diversifying

Being a one-trick pony can always prove risky. This rationale seems to have dawned on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company specializing in prescription cannabinoid medicine. Continue reading “GW Pharma Takes A Step Toward Diversifying”